GLAND
GenericsGLAND is a generic drug manufacturer focused on Oncology, Cardiovascular, Infectious Disease. Key products include MIDAZOLAM IN 0.9% SODIUM CHLORIDE.
GLAND's Key Drugs
GLAND's core commercial portfolio centers on ZOLEDRONIC, BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, MIDAZOLAM IN 0.9% SODIUM CHLORIDE, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
GLAND's Recent FDA Approvals
GLAND secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
GLAND's Therapeutic Areas
GLAND's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GLAND's Top Competitors
GLAND's closest competitors by therapeutic-area and drug-target overlap include Merck, GE HEALTHCARE, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GLAND Pipeline Snapshot
Active clinical trials for GLAND across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZOLEDRONIC leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 2013-08-05
- Latest
- 2026-06-11
- Applications
- 146